Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-Patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

Next Previous
Trial Profile

A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-Patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary) ; Risperidone
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 04 Mar 2009 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
  • 23 Jan 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
  • 07 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top